Key facts
- Notable investors include TusStar Incubator, Unity Ventures (China), Tsinghua Innovation Ventures, Ruisheng Equity, Beijing Weihua Yuanhe Capital Investment Management Center — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Everlife Biomed
- ·The full record, as it builds
Funding rounds
No funding rounds for Everlife Biomed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Everlife Biomed
Developer of Sertoli cell technology for regenerative medicine based in Beijing, China. The company uses cell reprogramming to develop Sertoli cells for stem cell research and development, enabling biomedical professionals to deliver more effective stem cell solutions to patients.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Employees
- 4
- Website
- everlifebiomed.com/
- Ownership
- Privately Held (backing)
Everlife Biomed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Everlife Biomed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Everlife Biomed in its N-PORT filings yet. We sweep new filings monthly.